A TriNetX global collaborative network retrospective cohort study on the impact of COVID-19 vaccination on juvenile idiopathic arthritis Authors: Su-Boon Yong, Ping-Hao Chiang, Chi Ya Yang, Ji Hung Wei, Chia-Jung Li, Chih-Wei Tseng, Shiow-Ing Wang, James Cheng-Chung Wei, Jiu-Yao Wang Published: 2026 ABSTRACT The objective is to determine the Impact of COVID-19 Vaccination and Medical Utilization in Juvenile Idiopathic Arthritis (JIA) patients. Our study retrieved data from the US Collaborative Network in TriNetX between January 1st, 2020, and June 30th, 2023. We investigated the incidence of COVID-19, medical utilization, and mortality in JIA patients. The HR and 95% CI of the outcomes were calculated between propensity score-matched (PSM) 1:1. 652 vaccinated and 652 unvaccinated JIA patients were enrolled. The vaccinated group demonstrated a significantly elevated risk of infection of COVID-19 but also a notably higher overall use of medical services, with a hazard ratio (HR) of 2.112 and a 95% confidence interval (C.I.) ranging from 1.081 to 4.129. No significant difference in the risk of outcomes comparing the COVID-19 vaccine group and the influenza vaccine group. During the Delta variant, vaccination was associated with a statistically non-significant rise in COVID-19 risk (HR = 1.402, 95% C.I.= 0.599–28.60). In the era of Omicron there was an increased rate of overall medical service use (HR = 2.326, 95% C.I.= 0.884–6.121). JIA patients were found to have higher risk of SARS-CoV-2 infection when vaccinated against COVID-19 compared to those who didn’t in this database study, keeping in mind confounders inherent to observational data and selection bias that may limit this conclusion, and could also be affected by different COVID-19 variants. Increased medical resource use was found in these patients but there was no significant rise in mortality, warranting further investigation into the vaccine’s impact on protection in JIA patients and immunological responses involved. Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52548-x. Introduction In recent years, the COVID-19 pandemic has profoundly affected global health, leading to significant mortality. Patients with comorbidities, particularly those with autoimmune diseases, have been identified as especially susceptible due to inherent immune dysfunctions and the use of immunosuppressive and immunomodulatory therapies. These factors have been linked to increased severity of COVID-19 and a higher incidence of complications1. Vaccines have provided a critical means of addressing this novel virus2–6. Consequently, individuals with autoimmune conditions have been prioritized for vaccination. However, the compromised immune function in these patients has been associated with variable vaccine responses and the occurrence of adverse events, including those affecting the joints7–9. The impact of commonly used treatments in this population, such as corticosteroids, csDMARDs, TNF inhibitors, and anti-CD20 agents, on vaccine efficacy—particularly in relation to humoral immunity—is a concern10. While organizations like EULAR have issued guidelines for vaccine administration and treatment strategies during the pandemic for specific patient subgroups, and many studies have investigated the immune response and safety of vaccines in this demographic, there remains a scarcity of research on the effectiveness of vaccines in safeguarding individuals with autoimmune diseases from infection, subsequent healthcare needs, and mortality. This gap is particularly notable in adolescent populations, who, despite generally better health and lower risk of severe outcomes, lack substantial research confirming vaccine efficacy11–13.. Juvenile idiopathic arthritis (JIA) encompasses a spectrum of subtypes, all characterized by arthritis with an onset prior to 16 years of age and of unknown etiology. The disease’s immunological underpinnings are increasingly recognized as complex, given the diversity of its subtypes. Synovial inflammation in JIA is linked to immune regulatory cells, including T-helper-17 cells and FOXP3-positive regulatory T cells14. Additionally, parallels between JIA and adult rheumatoid arthritis suggest a nuanced interplay with COVID-19.15There are differences in medical use patterns during the COVID-19 pandemic between patients with JIA and those with other types of AIRDs found in a previous study16. Given the unique vulnerabilities of JIA patients to COVID-19, targeted protective measures are imperative. The scarcity of JIA cases, coupled with its variable prevalence and clinical features, complicates the assessment of vaccine efficacy in these patients through randomized control trials. This study, therefore, leverages global databases to examine the protection for JIA patients during the pandemic. It goes beyond assessing the link between vaccination and COVID-19 incidence to explore differences in healthcare utilization, including hospitalization, emergency room visits, intensive care unit (ICU) admissions, ventilator usage, and all-cause mortality among these patients. The analysis also considers various factors such as gender, race, age, the two vaccine brands recommended for adolescents, and the prevalence of different COVID-19 variants, offering a comprehensive overview of the pandemic’s impact on this patient population. Methods Population, study design, and data collection The data used in this study was collected on June, 30th, 2023 from the TriNetX US Collaborative Network17, which provided access to electronic medical records of juvenile idiopathic arthritis, COVID-19, hospital inpatient services, mechanical ventilation, emergency department services, and critical care services from approximately 101 million patients from 60 healthcare organizations. The data used in this study represent a secondary analysis of existing, de-identified data, in accordance with the de-identification standard defined in Section § 164.514(a) of the HIPAA Privacy Rule. As such, the study does not involve intervention or interaction with human subjects and is approved by the Research Ethics Committee (REC) III of the China Medical University and Hospital protocol number CMUH113-REC3-099. Through this database, the inclusion criteria for this study were patients under the age of sixteen who had two medical visits and had been diagnosed with JIA through the ICD-10 code M08 between January 1 st, 2020, and June 30th, 2023. Furthermore, the exclusion criteria included patients who had been previously diagnosed with COVID-19 (with ICD-10 codes U07, U09, Z86.16, J12.81, J12.82, B97.29, B34.2, or a positive PCR9088 result) before or on the index date, as well as individuals who had passed away before or within 13 days after the index date. After that, patients with JIA under the age of sixteen, regardless of the brand, dosage, or frequency of COVID-19 vaccination, were included in the vaccinated cohort (Fig. 1.). Those who did not receive the COVID-19 vaccine were categorized into the unvaccinated cohort. Similarly, the vaccination status of all patients was identified through electronic records. Index dates were based on COVID-19 vaccination date for the vaccinated group and matched encounter date for unvaccinated controls. However, full temporal alignment was not feasible due to the natural distribution of vaccine uptake. Propensity-score matching The vaccinated cohort and unvaccinated cohort were stratified by age, sex, and race (White, Black or African American, Asian, and Unknown race). The lifestyle such as psychoactive substance use has also been balanced. Furthermore, the two cohorts were propensity-matched (1:1) for the following comorbidities and medication including acute upper respiratory infections, attention deficit hyperactivity disorder, asthma, overweight and obesity, atopic dermatitis, diabetes mellitus, glucocorticoids use, methotrexate(MTX) use, sulfasalazine use, and leflunomide use. Moreover, numeric data including BMI, CRP, and ESR were also matched. In the process of propensity score matching, the two cohorts of this study distributed similarly. Outcomes measurement Our study investigated the incidence of COVID-19, medical resource usage, and mortality in JIA patients, across four time intervals post-index date: fourteen days to three months, six months, nine months, and one year. COVID-19 cases were identified using ICD-10 codes U07.1 or U07.2, a positive PCR test (code 9088), pneumonia linked to COVID-19 (ICD-10 code J12.82), post-COVID-19 condition (ICD-10 code U09), or a past history of COVID-19 (ICD-10 code Z86.16). Medical utilization encompassed hospital inpatient services, mechanical ventilation, emergency department visits, and critical care, with specific codes. Mortality was determined based on the “deceased” status in the TriNetX database. Our study also adjusted for various variables to evaluate the risk of these outcomes, using four different models. Model 1 conducted a basic analysis without propensity score matching (crude model). Model 2 implemented propensity score matching for age, sex, and race. Model 3 added lifestyle factors and medical utilization to the matching criteria. Model 4, the most comprehensive, matched on the initial analysis criteria. Across all models, the results were directionally consistent and comparable in magnitude, indicating that our findings are robust to different matching specifications. While including medical utilization and other baseline factors helped improve covariate balance, our overall conclusions did not rely on their inclusion. Additionally, a sensitivity test was performed to compare COVID-19 risks between groups vaccinated for COVID-19 and influenza, aiming to reduce potential selection bias. Subgroup analysis Our research explored the impact of vaccination across different ethnicities through subgroup analyses and divided participants into two age groups: children under seven years and those aged seven to sixteen. We also segregated data based on gender, classifying participants as male or female. In terms of race, the impact of vaccination was specifically assessed for both White and Black or African American groups. We distinguished between recipients of the BNT and Moderna COVID-19 vaccines and separately assessed the impact of vaccination in two different timeframes: the Delta variant-led period from May 31, 2021, to November 25, 2021, and the Omicron variant-dominated span from November 26, 2021, to June 30, 2023. Statistical analysis The evaluation of the distribution between the COVID-19 vaccine injected and the unvaccinated cohort was using the standardized mean differences (SMD). The Kaplan-Meier approach was used in the study to demonstrate the COVID-19 incidence, medical utilization, and mortality. The comparison was made between the matched with and without vaccination cohort by log-rank test. The 1-year risk of each outcome was demonstrated by using the Cox proportional hazard model. Results The US Research Network’s database, encompassing 41,003,579 patients with a minimum of two visits between January 1, 2020, and June 30, 2023, identified 22,009 cases of JIA. Excluding those older than sixteen, the focused cohort consisted of 10,483 patients, of whom 743 were vaccinated against COVID-19 and 9,740 were not. Following the application of the stated exclusion criteria and 1:1 propensity score matching, the final cohorts consisted of 652 vaccinated and 652 unvaccinated individuals. (Fig. 1.) The average ages of the vaccinated and unvaccinated groups were 12.8 ± 3.6 and 12.5 ± 3.4 years, respectively, with a majority being female (64.3% vs. 62.9%) and white (68.1% vs. 64.0%). The most prevalent comorbidities in both cohorts were blood and immune system disorders (109 in the vaccinated group and 102 in the unvaccinated group), followed by anxiety, dissociative, stress-related, and other nonpsychotic mental disorders (97 in the vaccinated group and 103 in the unvaccinated group). Detailed comparisons of the two cohorts before and after matching are presented in Table 1.Fig. 1Flowchart of selection processTable 1Baseline characteristics of study subjects (before and after PSM matching).VariablesBefore PSMAfter PSMVaccinatedgroup(n = 664)Non-vaccinated group (n = 9485)SMDVaccinatedgroup(n = 652)Non-vaccinated group(n = 652)SMDAge at index Mean ± SD12.9 ± 3.610.3 ± 4.40.64512.8 ± 3.612.5 ± 3.40.088Sex, n (%) Female427 (64.3)6455 (68.1)0.079419 (64.3)410 (62.9)0.029 Male229 (34.5)3009 (31.7)0.059227 (34.8)239 (36.7)0.038Race, n (%) White448 (67.5)6758 (71.2)0.082444 (68.1)417 (64.0)0.088 Black or African American53 (08.0)616 (06.5)0.05751 (07.8)57 (08.7)0.033 Asian27 (04.1)213 (02.2)0.10425 (03.8)31 (04.8)0.045 American Indian or Alaska Native10 (01.5)62 (00.7)0.08310 (01.5)10 (01.5)0.000 Native Hawaiian or Other Pacific Islander10 (01.5)17 (00.2)0.14610 (01.5)10 (01.5)0.000 Other Race59 (08.9)678 (07.1)0.06457 (08.7)70 (10.7)0.067Family history, n (%) Family history of diabetes mellitus10 (01.5)40 (00.4)0.11110 (01.5)10 (01.5)0.000Lifestyles, n (%) Psychoactive substance use10 (01.5)10 (00.1)0.15710 (01.5)10 (01.5)0.000Medical utilization, n (%) Office or Other Outpatient Services506 (76.2)4823 (50.8)0.546495 (75.9)512 (78.5)0.062 Emergency Department Services71 (10.7)900 (09.5)0.04070 (10.7)74 (11.4)0.020 Hospital Inpatient Services26 (03.9)244 (02.6)0.07626 (04.0)24 (03.7)0.016 Preventive Medicine Services184 (27.7)551 (05.8)0.613173 (26.5)186 (28.5)0.045Comorbidities, n (%) Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism115 (17.3)949 (10.0)0.214109 (16.7)102 (15.6)0.029 Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders103 (15.5)456 (04.8)0.36097 (14.9)103 (15.8)0.026 Acute upper respiratory infections74 (11.1)586 (06.2)0.17772 (11.0)91 (14.0)0.088 Other diseases of upper respiratory tract68 (10.2)464 (04.9)0.20365 (10.0)72 (11.0)0.035 Attention-deficit hyperactivity disorders56 (08.4)244 (02.6)0.25952 (08.0)55 (08.4)0.017 Asthma56 (08.4)343 (03.6)0.20452 (08.0)52 (08.0)0.000 Overweight and obesity36 (05.4)265 (02.8)0.13335 (05.4)29 (04.4)0.043 Mood [affective] disorders46 (06.9)186 (02.0)0.24342 (06.4)48 (07.4)0.036 Other nutritional deficiencies35 (05.3)209 (02.2)0.16232 (04.9)26 (04.0)0.045 Vasomotor and allergic rhinitis44 (06.6)225 (02.4)0.20643 (06.6)49 (07.5)0.036 Neoplasms27 (04.1)152 (01.6)0.14926 (04.0)25 (03.8)0.008 Autistic disorder20 (03.0)110 (01.2)0.13020 (03.1)22 (03.4)0.017 Atopic dermatitis19 (02.9)86 (00.9)0.14415 (02.3)18 (02.8)0.029 Diabetes mellitus10 (01.5)71 (00.7)0.07210 (01.5)10 (01.5)0.000 Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence10 (01.5)14 (00.1)0.15010 (01.5)10 (01.5)0.000 Attention and concentration deficit10 (01.5)12 (00.1)0.15410 (01.5)10 (01.5)0.000 Other chronic obstructive pulmonary disease10 (01.5)10 (00.1)0.15710 (01.5)0 (00.0)0.177 Systemic lupus erythematosus (SLE)10 (01.5)58 (00.6)0.08710 (01.5)10 (01.5)0.000 Diaper dermatitis10 (01.5)19 (00.2)0.14210 (01.5)10 (01.5)0.000 Other salmonella infections0 (00.0)10 (00.1)0.0460 (00.0)0 (00.0)0.000Medications, n (%) Glucocorticoids198 (29.8)1902 (20.1)0.227193 (29.6)198 (30.4)0.017 Leflunomide19 (02.9)113 (01.2)0.11919 (02.9)17 (02.6)0.019 Sulfasalazine10 (01.5)77 (00.8)0.06510 (01.5)10 (01.5)0.000 Methotrexate174 (26.2)1812 (19.1)0.170172 (26.4)166 (25.5)0.021Laboratory, n (%) BMI, ≧ 30 Kg/m234 (05.1)236 (02.4)0.13733 (05.0)27 (04.1)0.043 Erythrocyte sedimentation rate, < 15 mm/h232 (34.9)2233 (23.5)0.252225 (34.5)211 (32.3)0.045 C reactive protein, < 3 mg/L47 (07.0)680 (07.1)0.00346 (07.0)68 (10.4)0.119Bold font represents a standardized mean difference was more than 0.1.If the patient is less or equal to 10, results show the count as 10. PSM: Propensity score matching, SMD: Standardized mean difference, SD: Standard deviation, BMI: Body mass index. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage. Flowchart of selection process Table 1Baseline characteristics of study subjects (before and after PSM matching).VariablesBefore PSMAfter PSMVaccinatedgroup(n = 664)Non-vaccinated group (n = 9485)SMDVaccinatedgroup(n = 652)Non-vaccinated group(n = 652)SMDAge at index Mean ± SD12.9 ± 3.610.3 ± 4.40.64512.8 ± 3.612.5 ± 3.40.088Sex, n (%) Female427 (64.3)6455 (68.1)0.079419 (64.3)410 (62.9)0.029 Male229 (34.5)3009 (31.7)0.059227 (34.8)239 (36.7)0.038Race, n (%) White448 (67.5)6758 (71.2)0.082444 (68.1)417 (64.0)0.088 Black or African American53 (08.0)616 (06.5)0.05751 (07.8)57 (08.7)0.033 Asian27 (04.1)213 (02.2)0.10425 (03.8)31 (04.8)0.045 American Indian or Alaska Native10 (01.5)62 (00.7)0.08310 (01.5)10 (01.5)0.000 Native Hawaiian or Other Pacific Islander10 (01.5)17 (00.2)0.14610 (01.5)10 (01.5)0.000 Other Race59 (08.9)678 (07.1)0.06457 (08.7)70 (10.7)0.067Family history, n (%) Family history of diabetes mellitus10 (01.5)40 (00.4)0.11110 (01.5)10 (01.5)0.000Lifestyles, n (%) Psychoactive substance use10 (01.5)10 (00.1)0.15710 (01.5)10 (01.5)0.000Medical utilization, n (%) Office or Other Outpatient Services506 (76.2)4823 (50.8)0.546495 (75.9)512 (78.5)0.062 Emergency Department Services71 (10.7)900 (09.5)0.04070 (10.7)74 (11.4)0.020 Hospital Inpatient Services26 (03.9)244 (02.6)0.07626 (04.0)24 (03.7)0.016 Preventive Medicine Services184 (27.7)551 (05.8)0.613173 (26.5)186 (28.5)0.045Comorbidities, n (%) Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism115 (17.3)949 (10.0)0.214109 (16.7)102 (15.6)0.029 Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders103 (15.5)456 (04.8)0.36097 (14.9)103 (15.8)0.026 Acute upper respiratory infections74 (11.1)586 (06.2)0.17772 (11.0)91 (14.0)0.088 Other diseases of upper respiratory tract68 (10.2)464 (04.9)0.20365 (10.0)72 (11.0)0.035 Attention-deficit hyperactivity disorders56 (08.4)244 (02.6)0.25952 (08.0)55 (08.4)0.017 Asthma56 (08.4)343 (03.6)0.20452 (08.0)52 (08.0)0.000 Overweight and obesity36 (05.4)265 (02.8)0.13335 (05.4)29 (04.4)0.043 Mood [affective] disorders46 (06.9)186 (02.0)0.24342 (06.4)48 (07.4)0.036 Other nutritional deficiencies35 (05.3)209 (02.2)0.16232 (04.9)26 (04.0)0.045 Vasomotor and allergic rhinitis44 (06.6)225 (02.4)0.20643 (06.6)49 (07.5)0.036 Neoplasms27 (04.1)152 (01.6)0.14926 (04.0)25 (03.8)0.008 Autistic disorder20 (03.0)110 (01.2)0.13020 (03.1)22 (03.4)0.017 Atopic dermatitis19 (02.9)86 (00.9)0.14415 (02.3)18 (02.8)0.029 Diabetes mellitus10 (01.5)71 (00.7)0.07210 (01.5)10 (01.5)0.000 Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence10 (01.5)14 (00.1)0.15010 (01.5)10 (01.5)0.000 Attention and concentration deficit10 (01.5)12 (00.1)0.15410 (01.5)10 (01.5)0.000 Other chronic obstructive pulmonary disease10 (01.5)10 (00.1)0.15710 (01.5)0 (00.0)0.177 Systemic lupus erythematosus (SLE)10 (01.5)58 (00.6)0.08710 (01.5)10 (01.5)0.000 Diaper dermatitis10 (01.5)19 (00.2)0.14210 (01.5)10 (01.5)0.000 Other salmonella infections0 (00.0)10 (00.1)0.0460 (00.0)0 (00.0)0.000Medications, n (%) Glucocorticoids198 (29.8)1902 (20.1)0.227193 (29.6)198 (30.4)0.017 Leflunomide19 (02.9)113 (01.2)0.11919 (02.9)17 (02.6)0.019 Sulfasalazine10 (01.5)77 (00.8)0.06510 (01.5)10 (01.5)0.000 Methotrexate174 (26.2)1812 (19.1)0.170172 (26.4)166 (25.5)0.021Laboratory, n (%) BMI, ≧ 30 Kg/m234 (05.1)236 (02.4)0.13733 (05.0)27 (04.1)0.043 Erythrocyte sedimentation rate, < 15 mm/h232 (34.9)2233 (23.5)0.252225 (34.5)211 (32.3)0.045 C reactive protein, < 3 mg/L47 (07.0)680 (07.1)0.00346 (07.0)68 (10.4)0.119Bold font represents a standardized mean difference was more than 0.1.If the patient is less or equal to 10, results show the count as 10. PSM: Propensity score matching, SMD: Standardized mean difference, SD: Standard deviation, BMI: Body mass index. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage. Baseline characteristics of study subjects (before and after PSM matching). Bold font represents a standardized mean difference was more than 0.1.If the patient is less or equal to 10, results show the count as 10. PSM: Propensity score matching, SMD: Standardized mean difference, SD: Standard deviation, BMI: Body mass index. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage. Throughout the follow-up duration of fourteen days to one year, there were 32 COVID-19 cases in the vaccinated group, in contrast to 14 cases among the unvaccinated. This discrepancy was statistically significant with HR 2.285 and 95% C.I. =1.219–4.282, as shown in Table 2. The comparative survival probability curves for COVID-19 in both the vaccinated and unvaccinated cohorts are depicted in Fig. 2. Additionally, the study’s focus on various post-vaccination time points consistently revealed significant differences in SARS-CoV-2 infection risk between the vaccinated and unvaccinated groups, except for the adjusted hazard ratio calculated for the period from fourteen days to three months post-index date (HR = 1.500, 95% C.I.=0.251–8.980), as shown in Supplementary Table 2. Moreover, when adjusting for various variables, the vaccinated cohort consistently demonstrated a higher risk of COVID-19 across all four models examined, detailed in Supplementary Table 1. Fig. 2Kaplan-Meier curve of COVID-19 infection incidence Kaplan-Meier curve of COVID-19 infection incidence The vaccinated cohort not only exhibited a heightened risk of infection of COVID-19 but also showed a significantly increased composite medical utilization, with a hazard ratio (HR) of 2.112 and a 95% confidence interval (C.I.) of 1.081 to 4.129. Although a similar pattern was observed in all-cause mortality, the difference between the vaccinated and unvaccinated cohorts was not statistically significant (HR = 2.975, 95% C.I.= 0.309 to 28.60) (Table 2). When analyzing the results over various time periods, they were consistent with those observed at the one-year follow-up. Notably, the highest hazard ratios were recorded when comparing the two cohorts from 14 days to 6 months post-index, as detailed in Supplementary Table 2.Table 2Risk of outcome (14 days to 1 year).OutcomesPatients with outcomeAdjusted hazard ratio(95% CI) aVaccinated groupNon-vaccinated groupCOVID-19 infection32142.285 (1.219–4.282)Medical utilization (composite)25132.112 (1.081–4.129)All-cause mortality10102.975 (0.309–28.60)Note:Note:If the patient is less or equal to 10, results show the count as 10. CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage.* Proportionality <0.001. Table 2Risk of outcome (14 days to 1 year).OutcomesPatients with outcomeAdjusted hazard ratio(95% CI) aVaccinated groupNon-vaccinated groupCOVID-19 infection32142.285 (1.219–4.282)Medical utilization (composite)25132.112 (1.081–4.129)All-cause mortality10102.975 (0.309–28.60)Note:Note:If the patient is less or equal to 10, results show the count as 10. CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage.* Proportionality <0.001. Risk of outcome (14 days to 1 year). Note: Note: If the patient is less or equal to 10, results show the count as 10. CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage. * Proportionality <0.001. Subgroup analysis indicated that there was no significant difference in COVID-19 risk among the vaccinated cohort, both in children under 6 years and those aged 7 to 16, as evidenced by the broad 95% confidence intervals (see Supplementary Table 3). This pattern was also observed across gender and racial subgroups (Supplementary Tables 4 and 5). In contrast, vaccination with the BNT vaccine was linked to an increased rate of composite medical utilization (HR = 2.529, 95% C.I.= 1.091–5.861), as shown in Supplementary Table 6. Notably, the risk of COVID-19 and the level of composite medical utilization exhibited differing trends during periods dominated by the Delta and Omicron variants. During the Delta variant’s predominance, vaccination correlated with a non-significant increase in COVID-19 risk (HR = 1.402, 95% C.I.= 0.599–28.60), while in the Omicron variant’s dominant period, it was associated with a higher rate of composite medical utilization (HR = 2.326, 95% C.I.= 0.884–6.121), as detailed in Supplementary Table 7. Forest plot of the overall subgroup analysis were shown in Fig. 3. Fig. 3Forest plot of adjusted hazard ratio for COVID-19 infection Forest plot of adjusted hazard ratio for COVID-19 infection Sensitivity analysis revealed no significant difference in the risk of outcomes when comparing the COVID-19 vaccine group to the influenza vaccine group, as detailed in Table 3.Table 3Risk of outcome (14 days to 1 year) Sensitivity analysis (modified control cohort into influenza vaccinated cohort).OutcomesPatients with outcomeAdjusted hazard ratio(95% CI) aVaccinated COVID-19 vaccine cohort(n = 389)Vaccinated influenza vaccine cohort(n = 389)COVID-19 infection18141.306 (0.650–2.626)Medical utilization (composite)17131.523 (0.740–3.136)All-cause mortality10101.014 (0.143–7.196)Note:CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage.* Proportionality <0.001 Table 3Risk of outcome (14 days to 1 year) Sensitivity analysis (modified control cohort into influenza vaccinated cohort).OutcomesPatients with outcomeAdjusted hazard ratio(95% CI) aVaccinated COVID-19 vaccine cohort(n = 389)Vaccinated influenza vaccine cohort(n = 389)COVID-19 infection18141.306 (0.650–2.626)Medical utilization (composite)17131.523 (0.740–3.136)All-cause mortality10101.014 (0.143–7.196)Note:CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage.* Proportionality <0.001 Risk of outcome (14 days to 1 year) Sensitivity analysis (modified control cohort into influenza vaccinated cohort). Note:CI: Confidence interval. NA: Not applicable. a. Propensity score matching was performed on age at index, sex, race, lifestyles, medical utilization, comorbidities, and medication usage.* Proportionality <0.001 Discussion Our study demonstrated a significant correlation between COVID-19 vaccination and an elevated incidence of COVID-19 among adolescents with Juvenile Idiopathic Arthritis (JIA) and higher healthcare resource utilization. The marked increase in healthcare resource utilization in the vaccinated cohort is evidenced by higher rates of hospital admissions, emergency room visits, mechanical ventilation usage, and intensive care unit (ICU). However, the study did not find a significant link between vaccination and overall mortality rates. Large-scale clinical trials have previously confirmed the efficacy of the BNT162b2 vaccine in individuals 16 years and older. For instance, a two-month follow-up showed only 8 COVID-19 cases among 21,720 vaccine recipients, indicating a 95% effectiveness rate2. In the 12 to 15 age group, those receiving two doses of BNT162b2 exhibited higher neutralizing antibody levels than those aged 16 to 25, with no COVID-19 cases reported in the vaccinated group during the observation period11. In a study of the mRNA-1273 vaccine for 6 to 11-year-olds, vaccine efficacy was estimated at 88.0%, with 7 cases (0.3%) reported in the vaccinated group during the delta variant’s predominance18. Further research showed vaccine efficacies of 36.8% in 2-to-5-year-olds and 50.6% in 6-to-23-month-olds during the omicron variant’s surge19. However, the present study, encompassing a more extended one-year follow-up and including various dominant virus variants, found that vaccinated adolescents with JIA faced a significantly higher risk of contracting COVID-19. The incidence rate per 1000 person-years was considerably higher in the vaccinated JIA group (49.1) compared to the mRNA-1273 study in 6 to 11-year-olds (14.0).19Even in a prior study of the BNT162b2 vaccine for children aged 6–11, which had a median follow-up of 2.3 months, there were only 3 COVID-19 cases among 1,305 vaccine recipients12. These discrepancies could be due to differences in follow-up duration, participant age, health conditions, and varying regional and temporal contexts. However, the observed increased risk in this particular group over the entire study duration calls for more focused attention and in-depth research into the effects of vaccines on this specific population. Our study indicated that COVID-19 vaccination in the juvenile idiopathic arthritis (JIA) cohort was linked with an elevated risk of COVID-19 infection and increased healthcare usage, which contrasts with earlier studies on vaccine safety and immune response in this demographic. In Poland, two centers evaluated JIA patients’ outcomes pre- and post-COVID-19 vaccination, noting that most side effects mirrored those in the general population. Interestingly, active disease rates in these patients decreased from 30.2% pre-vaccination to 18.6% post-vaccination. The level of JADAS-27 activity was more pronounced in the cohort prior to vaccination20. A Greek study focusing on JIA adolescents on TNFi/MTX therapy who were administered two doses of the Pfizer-BioNTech vaccine reported a 100% seropositivity rate. These individuals maintained robust humoral responses to SARS-CoV-2 in the first and third months post-vaccination, irrespective of JIA types or medications used, with no dropouts due to disease flares or vaccine-related side effects21. However, this trend was noted only during the initial three months, as antibody levels significantly dwindled by the sixth month22. Data from Clalit Health Services demonstrated comparable efficacy of the BNT162b2 mRNA vaccine in preventing COVID-19 in both populations with and without juvenile-onset inflammatory or immune rheumatic diseases, with a 99.2% effectiveness for the three-dose regimen23. Increased healthcare-seeking behavior and testing frequency among vaccinated children with chronic diseases could can have detection bias24. Moreover, patients with more active or severe disease may have been prioritized for vaccination by clinicians due to their perceived vulnerability. This selection bias could lead to an overrepresentation of higher-risk patients in the vaccinated group, potentially explaining the observed increase in infection and healthcare utilization. waning immunity, especially during the Omicron wave, may have affected vaccine effectiveness and is a potential source of misinterpretation25. Our findings should not be interpreted as evidence against vaccination, but rather as a signal warranting further investigation using prospective data and more granular covariate adjustment. JIA patients who received COVID-19 vaccination showed significantly higher medical resource utilization, indicating possibly baseline higher severity of disease in this group of patients. Whether the effect of the COVID-19 vaccine would be decreased when applied to more severe JIA patients versus those with less severity is yet to be explored with real-world data. In the subgroup analysis, the risk of COVID-19 among the vaccinated was not statistically significant but was observed to be higher than that in the unvaccinated group during the Delta variant’s predominance. This trend, however, shifted during the Omicron variant’s surge, where the vaccinated group showed a higher rate of healthcare resource usage. A multi-center study across 21 U.S. hospitals assessed the efficacy of mRNA vaccines in preventing hospital admissions across different COVID-19 variants. The findings indicated varying efficacies for the Delta (two doses: 85%, three doses: 94%) and Omicron (two doses: 65%, three doses: 86%) variants26. Additionally, a longitudinal observational study, utilizing the ZOE COVID app, reported a reduced hospitalization rate during the Omicron phase (1.9% vs. 2.6%, OR 0.75; 95% CI 0.57–0.98, p= 0.03), suggesting a possible decline in medical resource use among the unvaccinated during this period, while vaccine-related factors potentially contributed to continued healthcare utilization in the vaccinated group27. Moreover, the BNT vaccine was linked to a notable increase in overall healthcare utilization, potentially due to vaccine-induced side effects. A study of 246 individuals with childhood-onset rheumatic diseases, who received either the CoronaVac inactivated SARS-CoV-2 or the BNT162b2 mRNA COVID-19 vaccine, found that 27 participants (12.1%) experienced disease flares within a month. Notably, severe side effects were rare but more prevalent in those receiving the BNT162b2 mRNA vaccine, with two of the three severe cases occurring in patients with familial Mediterranean fever. This suggests a higher incidence of side effects with the BNT162b2 vaccine (P < 0.001).28 In our study, despite leveraging a substantial database and employing a meticulous study methodology, several limitations were present. First, encompassing cohorts with increased healthcare engagement might have overlooked asymptomatic COVID-19 cases, although the likelihood of substantial underreporting of disease incidence in this closely monitored population is considered minimal relative to prior studies. Second, the exclusive reliance on pertinent medical records may under-report COVID-19 cases, or affect its correlation with healthcare utilization and mortality. Vaccinated children may have had better healthcare access, leading to higher likelihood of routine screening, diagnosis, or coding of COVID-19-related visits29. Ascertainment bias may be related to higher documented infection or utilization rates without implying a causal adverse effect of vaccination30. Third, this study’s inability to gauge autoimmune disease activity might affect decisions related to vaccination among physicians and patients. Severity is not able to be categorized, only the diagnosis of JIA. We did not have access to composite disease activity scores such as JADAS or detailed clinical parameters like joint counts in the dataset used, nor flare frequency or medication escalation details, therefore they were not included for propensity score matching. Fourth, we were unable to identify the specific COVID-19 variant. The use of calendar-time windows as variant proxies (rather than sequencing-confirmed variant data) limits the precision of our variant-related analysis. Moreover, we did not assess the prevalence of other autoimmune diseases or perform stratified analyses based on comorbidity profiles, and therefore cannot draw conclusions about their impact on infection risk in this context. Lastly, the study’s reliance on a database limited to certain medical institutions could lead to some oversight in tracking, yet the database’s proven reliability in past research, coupled with our rigorous design and multiple validation strategies, reinforces the study’s credibility. Future studies with larger sample sizes incorporating comprehensive clinical data, including standardized disease activity scores, medication dosing regimens, and patient-reported outcomes, are needed to disentangle the effects of vaccination from underlying disease severity. In summary, comprehensive analyses of the data through models and sensitivity analyses have established that adolescents with Juvenile Idiopathic Arthritis (JIA) showed an increased likelihood of SARS-CoV-2 infection when vaccinated against COVID-19. Although this heightened risk did not translate into a significant increase in overall mortality, it corresponded with increased use of medical resources. These findings do not imply that vaccination is detrimental. We must carefully interpret this finding by keeping in mind there are confounders and selection bias that could have contributed to the results of this observational data, and that different variants of COVID-19 could also present with different results of risks. Further investigation is necessary to uncover the vaccine’s impact and the immunological interactions with JIA. . Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1